News

Article

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and Management-01-06-2016
Volume12
Issue 1

GENEWIZ Acquires Beckman Coulter Gene Services

GENEWIZ signs definitive agreement to acquire Beckman Coulter's gene services business.

Genomics service provider, GENEWIZ, has signed a definitive agreement to acquire the genomic services business of Beckman Coulter (GS), according to a Dec. 21, 2015 announcement.

GENEWIZ provides Sanger DNA sequencing, gene synthesis, next generation sequencing, molecular biology bioinformatics, and GLP/GLIA regulatory services. The gene sequencing division of Beckman Coulter provides Sanger and next generation gene sequencing services, with bioinformatics services.

This acquisition will support GENEWIZ’s global expansion strategy by leveraging GS’s 25-plus years of genomics capabilities. It will also aid the company’s international expansion by adding additional locations in the US, UK, China, and Japan.

The agreement was approved by the boards of directors of both companies and closed immediately.  

Source: GENEWIZ

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content